US FDA sets deadline for removal of CFC epinephrine inhalers
This article was originally published in SRA
The US Food and Drug Administration has set a deadline of 31 December 2011 for manufacturers to take over-the-counter epinephrine metered-dose inhalers containing chlorofluorocarbons off the market. The cut-off date in the final rule on use of ozone-depleting substances; removal of essential-use designation (epinephrine)1 is a year later than the one suggested in the proposed rule that the FDA issued in September 20072,3. This will give manufacturers and users enough time for a properly informed transition to non-CFC alternatives such as prescription albuterol/levalbuterol MDIs that use hydrofluoroalkanes (HFA) as a propellant, the agency believes.
You may also be interested in...
HemaQuest, a US biotech focused on developing small-molecule therapeutics for haemoglobin diseases, has expanded the Phase II programme for its lead compound, HQK-1001, in sickle cell disease with a new trial aimed at establishing safety and tolerability at higher dose levels and over a longer course of therapy.
Novartis' efforts to revive its COX-2 inhibitor lumiracoxib under a new brand name, and with the risk of hepatotoxicity that killed the drug in its original incarnation muted by a companion diagnostic, have stumbled in Europe after the company withdrew an application for centralised approval of what is now known as Joicela.
Crystallics, a new contract research organisation specialising in solid-state research and pre-formulation activities for the pharmaceutical, biotechnology and agrochemical industries, has been established in the Netherlands through a management buyout of the former Avantium Pharma business from its parent company, Avantium Holding.